Brought to you by 
Bayer Agrees to Acquire Asklepios Biopharmaceutical for up to $4B; Closed
28 Jan 2021
Executive Summary
Bayer AG and privately held clinical-stage gene therapy company Asklepios BioPharmaceutical (AskBio) announced an agreement under which Bayer will acquire AskBio. Closing of the transaction is contingent upon the receipt of certain regulatory approvals, and is expected to take place during Q4 2020.
Deal Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer Agrees to Acquire Asklepios Biopharmaceutical for up to $4B; Closed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice